{
  "id": 520,
  "text": "# NCCN宫颈癌指南2024.V1版较2023.V1版更新内容（续） CERV-F 1/3 宫颈癌的全身治疗 鳞状细胞癌、腺癌或腺鳞癌 ![](images/5f3249131da5b7102251609d0c3f7f2fd153a2a89bf8517ac68126c2586aaade.jpg) # NCCN宫颈癌指南2024.V1版较2023.V1版更新内容（续） CERV-F 1/3 宫颈癌的全身治疗——宫颈小细胞神经内分泌癌 # CERV-F 2 of 3 Small Cell NECC ↓ Recurrent or Metastatic Disease Second-line orSubsequent Therapy; OtherRecommended Regimens:lrinotecanchanged fromcategory 2Btocategory A Footnote f added: NCCN Guidelines for the Management of Immunotherapy-Related Toxicities.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: # NCCN宫颈癌指南2024.V1版较2023.V1版更新内容（续） CERV-F 1/3 宫颈癌的全身治疗 鳞状细胞癌、腺癌或腺鳞癌 ![](images/5f3249131da5b7102251609d0c3f7f2fd153a2a89bf8517ac68126c2586aaade.jpg) # NCCN宫颈癌指南2024.V1版较2023.V1版更新内容（续） CERV-F 1/3 宫颈癌的全身治疗——宫颈小细胞神经内分泌癌 # CERV-F 2 of 3 Small Cell NECC ↓ Recurrent or Metastatic Disease Second-line orSubsequent Therapy; OtherRecommended Regimens:lrinotecanchanged fromcategory 2Btocategory A Footnote \n\n<question>: ",
  "ChatGPT_response_0": "NCCN宫颈癌指南2024.V1版相较于2023.V1版的更新内容包括针对鳞状细胞癌、腺癌或腺鳞癌以及宫颈小细胞神经内分泌癌的全身治疗方案。针对这些类型的宫颈癌，指南提供了针对复发性或转移性疾病的二线或后续治疗建议，包括紫杉醇等治疗方案。这些更新内容旨在帮助临床医生更好地制定个体化的治疗方案，提高患者的治疗效果和生存率。",
  "query": "NCCN宫颈癌指南2024.V1版相较于2023.V1版的更新内容，特别涉及哪些类型的全身治疗？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: NCCN宫颈癌指南2024.V1版相较于2023.V1版的更新内容，特别涉及哪些类型的全身治疗？\n\n<reference text>: # NCCN宫颈癌指南2024.V1版较2023.V1版更新内容（续） CERV-F 1/3 宫颈癌的全身治疗 鳞状细胞癌、腺癌或腺鳞癌 ![](images/5f3249131da5b7102251609d0c3f7f2fd153a2a89bf8517ac68126c2586aaade.jpg) # NCCN宫颈癌指南2024.V1版较2023.V1版更新内容（续） CERV-F 1/3 宫颈癌的全身治疗——宫颈小细胞神经内分泌癌 # CERV-F 2 of 3 Small Cell NECC ↓ Recurrent or Metastatic Disease Second-line orSubsequent Therapy; OtherRecommended Regimens:lrinotecanchanged fromcategory 2Btocategory A Footnote f added: NCCN Guidelines for the Management of Immunotherapy-Related Toxicities.\n\n<reply>: ",
  "response": "NCCN宫颈癌指南2024.V1版相较于2023.V1版的更新内容包括针对鳞状细胞癌、腺癌或腺鳞癌以及宫颈小细胞神经内分泌癌的全身治疗方案。针对这些类型的宫颈癌，指南提供了针对复发性或转移性疾病的二线或后续治疗建议，包括紫杉醇等治疗方案。这些更新内容旨在帮助临床医生更好地制定个体化的治疗方案，提高患者的治疗效果和生存率。"
}